The renal effects of noradrenaline and dopamine

Contributions to Nephrology

Volumn 132, Issue , 2001, Pages 146-157

  Bellomo, Rinaldo ^a   Ronco, Claudio ^b  

^a AUSTIN HEALTH   (Australia)

^b SAN BORTOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; NORADRENALIN;

BLOOD PRESSURE; DRUG EFFECT; HUMAN; KIDNEY; PHYSIOLOGY; REVIEW;

BLOOD PRESSURE; DOPAMINE; HUMANS; KIDNEY; NOREPINEPHRINE;

EID: 0035532674     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000060088     Document Type: Article

References (56)

1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Committee: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1658-1662.
2. Schreuder WO, Schneider AJ, Groeneveld ABJ, et al: Effect of dopamine vs. norepinephrine on hemodynamics in septic shock. Chest 1989;95:1282-1288.
3. Martin C, Papazian L, Perrin G, et al: Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993;103:1826-1831.
4. Desjars P, Pinaud M, Potel G, et al: A reappraisal of norepinephrine therapy in human septic shock. Crit Care Med 1987;15:134-137.
5. Moran JL, O'Fathartaigh M, Peisach AR, et al: Epinephrine as an inotropic agent in septic shock: A dose profile analysis. Crit Care Med 1993;21:70-77.
6. Pawlik W, Sheperd AP, Jacobson ED: Effect of vasoactive agents on intestinal oxygen consumption and blood flow in dogs. J Clin Invest 1975;56:484-490.
7. Sheperd AP, Pawlik W, Mailman D, Burks TF, Jacobson ED: Effects of vasoconstrictors on intestinal vascular resistance and oxygen extraction. Am J Physiol 1976;230:298-303.
8. Gombos EA, Hulet WH, Bopp P, et al: Reactivity of renal and systemic circulations to vasoconstrictor agents in normotensive and hypertensive subjects. J Clin Invest 1962;41:203-207.
9. Mills LC, Moyer JH, Handley CA: Effects of various sympathomimetic drugs on renal hemodynamics in normotensive and hypotensive dogs. Am J Physiol 1960;- 198:1279-1285.
10. Richer M, Robert S, Lebel M: Renal hemodynamics during norepinephrine and low-dose dopamine infusions in man. Crit Care Med 1996;24:1150-1156.
11. Deitch EA, Winterton J, Bey R: The gut as the portal of entry for bacteremia. Ann Surg 1987;205:681-692.
12. Schott CA, Gray GA, Stoclet JC: Dependence of endotoxin-induced vascular hyporeactivity on extracellular L-arginine. Br J Pharmacol 1993;108:38-43.
13. Kilbourn RO, Gross SS, Jubran A, et al: N-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: Implications for the involvement of nitric oxide. Proc Natl Acad Sci USA 1990;87:3629-3632.
14. 2 in endotoxemic dogs during shock and resuscitation. J Appl Physiol 1994;76:793-800.
15. Cronin RE, De Torrente A, Miller PD, Bulger RE, Burke TJ, Schrier RW: Pathogenic mechanisms in early norepinepherine-induced acute renal failure: Functional and histological correlates of protection. Kidney Int 1978;14:115-125.
16. Cronin R, Erickson AM, De Torrente A, McDonald KM, Schrier RW: Norepinepherine-induced acute renal failure: A reversible ischemic model of acute renal failure. Kidney Int 1978;14:187-190.
17. Schaer GL, Fink MP, Parrillo JE: Norepinephrine alone versus norepinephrine plus low-dose dopamine: Enhanced renal blood flow with combination pressor therapy. Crit Care Med 1985;13:492-496.
18. Anderson WP, Korner PI, Selig SE: Mechanisms involved in the renal responses to intravenous and renal artery infusions of noradrenaline in conscious dogs. J Physiol 1981;321:21-30.
19. Korner PI, Dorward PK, Blombery PA, Frean GJ: Central nervous beta-adrenoreceptors and their role in the cardiovascular action of propranolol in rabbits. Circ Res 1967;20:676-685.
20. Zhang H, Smail N, Cabral A, Rogiers P, Vincent JL: Effects of norepinephrine on regional blood flow and oxygen extraction capabilities during endotoxic shock. Am J Respir Crit Care Med 1997;155:1965-1971.
21. Bersten AD, Rutten AJ: Renovascular interaction of epinephrine, dopamine, and intraperitoneal sepsis. Crit Care Med 1995;23:537-544.
22. Bersten AD, Rutten AJ, Summersides G, et al: Epinephrine infusion in the sheep: Systemic and renal hemodynamic effects. Crit Care Med 1994;22:994-1001.
23. Bellomo R, Kellum JA, Wisniewski SR, Pinsky MR: Effects of norepinephrine on the renal vasculature in normal and endotoxemic dogs. Am J Respir Crit Care Med 1999;- 159:1186-1192.
24. Hesselvik JF, Brodin B: Low-dose norepinephrine in patients with septic shock and oliguria: Effects on afterload, urine flow, and oxygen transport. Crit Care Med 1989;- 17:179-180.
25. Meadows D, Edwards JD, Wilkins RG, et al: Reversal of intractable septic shock with norepinephrine therapy. Crit Care Med 1988;16:663-666.
26. Martin C, Eon B, Saux P, Aknin P, Gouin F: Renal effects of norepinephrine used to treat septic shock patients. Crit Care Med 1990;18:282-285.
27. Desjars P, Pinaud M, Bugnon D, Tasseau F: Norepinephrine therapy has no deleterious renal effects in human septic shock. Crit Care Med 1990;18:1048-1049.
28. Rudis MI, Basha MA, Zarowitz BJ: Is it time to reposition vasopressors and inotropes in sepsis? Crit Care Med 1996;24:525-537.
29. Redl-Wenzel EM, Armbruster C, Edelmann G, et al: The effects of norepinephrine on hemodynamics and renal function in severe septic shock states. Intensive Care Med 1993;19:151-154.
30. Bellomo R, Ronco C: The use of inotropic and vasopressor agents in patients at risk of renal dysfunction. In Ronco C, Bellomo R (eds): Critical Care Nephrology. Dordrecht, Kluwer Academic, 1998, pp 1133-1138.
31. Martin C, Viviand X, Leone M, Thirion X: Effect of norepinephrine on the outcome of septic shock. Crit Care Med 2000;28:2758-2765.
32. Hollenberg NK, Adams DF, Mendall P, et al: Renal vascular responses to dopamine: Hemodynamic and angiographie observations in normal man. Clin Sci 1973;45:733-742.
33. Cuthbertson BH, Noble DW: Dopamine in oliguria. BMJ 1997;314:690-691.
34. Chertow GM, Sayegh MH, Allgren RL, Lazarus JM: Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure? Am J Med 1996;101:49-53.
35. Van den Berghe G, de Zeager F: Anterior pituitary function during critical illness and dopamine treatment. Crit Care Med 1996;24:1580-1590.
36. Devins SS, Miller A, Herndon BL, O'Toole L, Reisz G: Effects of dopamine on T-lymphocyte proliferative responses and serum prolactin concentrations in critically ill patients. Crit Care Med 1992;20:1644-1649.
37. Segal JM, Phang PT, Walley KR: Low-dose dopamine hastens onset of gut ischemia in a porcine model of hemorrhagic shock. J Appl Physiol 1992;73:1159-1164.
38. Denton MD, Chertow GM, Brady HR: 'Renal-dose' dopamine for the treatment of acute renal failure: Scientific rationale, experimental studies and clinical trials. Kidney Int 1996;49:4-14.
39. Lee MR: Dopamine and the kidney: Ten years on. Clin Sci 1993;84:357-375.
40. Brezis M, Rosen S, Silva P, Epstein FH: Renal ischemia: A new perspective. Kidney Int 1984;26:375-383.
41. Kellum JA: The use of diuretics and dopamine in acute renal failure: A systematic review of the evidence. Crit Care 1997;1:53-59.
42. Myles PS, Buckland MR, Schenk NJ, et al: Effect of 'renal-dose' dopamine on renal function following cardiac surgery. Anaesth Intens Care 1993;21:56-61.
43. Swygert TH, Roberts LC, Valek TR, et al: Effect of intraoperative low-dose dopamine on renal function in liver transplant patients. Anesthesiology 1991;75:571-576.
44. Poison RJ, Park GR, Lindop MJ, Farman JV, Calne RY, Williams R: The prevention of renal impairment in patients undergoing orthotopic liver grafting by infusion of low dose dopamine. Anaesthesia 1987;42:15-19.
45. Parks RW, Diamond T, McCrory DC, Johnston GW, Rowlands BJ: Prospective study of postoperative renal function in obstructive jaundice and the effect of perioperative dopamine. Br J Surg 1994;81:437-439.
46. Hall KA, Wong RW, Hunter GC, et al: Contrast-induced nephrotoxicity: The effects of vasodilator therapy. J Surg Res 1992;53:317-320.
47. Weisberg LS, Kurnik PB, Kurnik BR: Dopamine and renal blood flow in radiocontrast-induced nephropathy in humans. Ren Fail 1993;15:61-68.
48. Grundmann R, Kindler J, Meider G, Stowe H, Sieberth HG, Pichlmaier H: Dopamine treatment of human cadaveric kidney graft recipients: A prospective randomized trial. Klin Wochenschr 1982;60:193-197.
49. Sandberg J, Tyden G, Groth CG: Low-dose dopamine infusion following cadaveric renal transplantation. No effect on incidence of ATN. Transplant Proc 1992;24:357.
50. Kadieva VS, Friedman L, Margolius LP, Jackson SA, Morrell DF: The effect of dopamine on graft function in patients undergoing renal transplantation. Anesth Analg 1993;76:362-365.
51. Duke GJ, Briedis JH, Weaver RA: Renal support in critically ill patients: Low-dose dopamine or low-dose dobutamine? Crit Care Med 1994;22:1919-1925.
52. Allen E, Pettigrew A, Frank D, et al: Alterations in dopamine clearance and catechol-O-methyltransferase activity by dopamine infusions in children. Crit Care Med 1997;25:181-189.
53. Juste RN, Moran L, Hooper J, Soni N: Dopamine clearance in critically ill patients. Intensive Care Med 1998;24:1217-1220.
54. Szerlip HM: Renal-dose dopamine: Fact or fiction. Ann Intern Med 1991;115:153-154.
55. Thompson BT, Cockrill BA: Renal-dose dopamine: A siren song. Lancet 1994;344:7-8.
56. ANLICS Clinical Trials Group: Low-dose dopamine in patients with renal dysfunction: A placebo-controlled trial. Lancet 2000;356:2139-2143.